A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer

Annals of Oncology

Volumn 22, Issue 8, 2011, Pages 1798-1804

  Schmittel, A ^a   Sebastian, M ^b   Fischer von Weikersthal, L ^c   Martus, P ^a   Gauler, T C ^d   Kaufmann, C ^a   Hortig, P ^a   Fischer, J R ^e   Link, H ^f   Binder, D ^a   Fischer, B ^b   Caca, K ^g   Eberhardt, W E E ^d   Keilholz, U ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c Medizinisches Versorgungszentrum Gesundheitszentrum   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e L wenstein Hospital   (Germany)

^f Westpfalz Klinikum GmbH   (Germany)

^g KLINIKUM LUDWIGSBURG   (Germany)

Author keywords

Carboplatin; Etoposide; Extensive disease; Irinotecan; SCLC; Trial

Indexed keywords

CARBOPLATIN; ETOPOSIDE; IRINOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CANCER REGRESSION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; GERMANY; HUMAN; INFECTION; LEUKOPENIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 79960990421     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq652     Document Type: Article

References (13)

1. Skarlos DV, Samantas E, Kosmidis P et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 1994; 5: 601-607.
2. Lassen U, Kristjansen PE, Osterlind K et al. Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up. Ann Oncol 1996; 7: 365-371.
3. Noda K, Nishiwaki Y, Kawahara M et al. Irinotecan plus Cisplatin compared with etoposide plus cisplatin for extensive small lung cancer. N Engl J Med 2002; 346: 85-91.
4. Hermes A, Bergman B, Bremnes R et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol 2008; 26: 4261-4267.
5. Hanna N, Bunn PA Jr, Langer C et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006; 24: 2038-2043.
6. Lara PN, Natale R, Crowley J et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009; 27: 2530-2535.
7. Zatloukal P, Cardenal F, Szczesna A et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol 2010; 21: 1810-1816.
8. Schmittel A, Schulze K, Hütter G et al. Phase I dose escalation study of carboplatin to a fixed dose of irinotecan as first-line treatment of small cell lung cancer. Onkologie 2004; 27: 280-284.
9. Wolf M, Teesen HW, Goerg C et al. Determining carboplatin/etoposide dosage in extensive stage small-cell lung cancer (SCLC). Ann Oncol 1991; 2: 361-364.
10. Schmittel A, Fischer von Weikersthal L, Sebastian M et al. A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extensive disease small-cell lung cancer. Ann Oncol 2006; 17: 663-667.
11. Cecchin E, Innocenti F, D'Andrea M et al. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol 2009; 27: 2457-2465.
12. Jelliffe RW. Creatinine clearance: bedside estimate. Ann Intern Med 1973; 79: 604-605(Letter).
13. Beutler E, Gelbart T, Demina A. Racial variability in the UDPglucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 1998; 95: 8170-8174.